Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2006

View Archived Issues

FabI inhibitors shown effective against staphylococci

AN-0900's encouraging results in preclinical models of anthrax infection

ATH-18534: targets pneumonia bacterial pathogenicity

Hemispherx Biopharma reports on "excellent year"

Dusa to acquire Sirius Laboratories

Fast track designation for HuMax-EGFr in head and neck cancer

Wyeth and Trubion form strategic alliance in inflammatory disease and cancer

Bristol-Myers Squibb files sBLA for third-party manufacturing of Orencia

Sativex cleared for U.S. phase III trials

Neose Technologies cleared to study NE-180 in phase I trial

Morphotek inlicenses antibody for mesothelin-expressing cancers

Versatile topical DNA vaccine undergoes preliminary clinical study in HIV

Northfield to receive defense appropriation for PolyHeme development

Orphan drug designation for CellCept in myasthenia gravis

Ecopia BioSciences seeks clearance for phase I Canadian study of ECO-4601

Epix ramps up phase IIa study of fibrin-binding imaging agent EP-2104R

Bayer purchases GlaxoSmithKline's European telmisartan rights

Gardasil submitted for Australian approval

KW-3902 improves fluid elimination and renal function in heart failure patients

Novel agents with potential in the treatment of anxiety, depression, etc. revealed in recent patents

Climara Pro approved for prevention of postmenopausal osteoporosis

Recent patents describe possible new agents for diabetes

Phase II trial investigates iPlex for myotonic muscular dystrophy

Novel treatments for cancer subject of several recent patents

Phase II trial for NT-501 in dry AMD

Success of universal toddler Havrix(R) vaccination program in endemic hepatitis A population

Synergistic antidepressant effects seen with M-100907 and fluoxetine

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...